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Pietro Caironi4,5, Serge Masson3, Giuseppe Baselli1, Giuseppe Ristagno  3, Luciano Gattinoni6, 
Eliandre de Oliveira2, Roberta Pastorelli3 & Manuela Ferrario  1
In this work, we examined plasma metabolome, proteome and clinical features in patients with severe 
septic shock enrolled in the multicenter ALBIOS study. The objective was to identify changes in the 
levels of metabolites involved in septic shock progression and to integrate this information with the 
variation occurring in proteins and clinical data. Mass spectrometry-based targeted metabolomics and 
untargeted proteomics allowed us to quantify absolute metabolites concentration and relative proteins 
abundance. We computed the ratio D7/D1 to take into account their variation from day 1 (D1) to day 7 
(D7) after shock diagnosis. Patients were divided into two groups according to 28-day mortality. Three 
different elastic net logistic regression models were built: one on metabolites only, one on metabolites 
and proteins and one to integrate metabolomics and proteomics data with clinical parameters. Linear 
discriminant analysis and Partial least squares Discriminant Analysis were also implemented. All the 
obtained models correctly classified the observations in the testing set. By looking at the variable 
importance (VIP) and the selected features, the integration of metabolomics with proteomics data 
showed the importance of circulating lipids and coagulation cascade in septic shock progression, thus 
capturing a further layer of biological information complementary to metabolomics information.
In the last decade, advances in high-throughput proteomic and metabolomic techniques allowed to evaluate the 
association of genetic and phenotypic variability with disease progression. This aspect is fundamental in case of 
complex multifactorial syndromes, such as sepsis and septic shock, which are both characterized by a response to 
treatment different from patient to patient and extremely difficult to predict. Moreover, the same root cause (e.g. 
source of primary infection or pathogen) may lead to significantly different clinical phenotypes and outcomes.
In recent years, the number of software aiming at integrating multiomics data is increasing1. The term 
“multi-omics data integration” refers to a new scientific request of combining multiple sources of information 
(omics) to provide deeper biological understanding. However, the majority of them are mainly devoted for inter-
preting genomics data and are based on a mechanistic interpretation, as the network-based (NB) approaches that 
take into account currently known (e.g. protein-protein interactions) or predicted (e.g. from correlation analysis) 
relationships between biological variables1. In this class, graph measures (e.g. degree, connectivity, centrality) and 
graph algorithms (e.g. sub-network identification) are used to identify valuable biological information. A differ-
ent approach is based on statistical methods in order to find possible associations among variables and outcomes. 
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Many softwares based on mathematical approaches usually adopted for data-mining or machine learning, are 
now freely available2. They are developed in MatlabTM or R environment and perform specific analyses on data 
given as input without any further constrains3,4. The availability of such software has encouraged this field, but 
has not solved the problem how to deal with different types of data (e.g. different standards and different normal-
ization approaches) and how to deal with a low number of observations, highly correlated variables, cross-over or 
longitudinal study. Different type of dataset requires different approaches and strategies. The comparison of the 
results from different models represents a valuable approach to support any possible associations found among 
variables.
In this study, we examined plasma metabolome, proteome and clinical features in a subset of patients with 
the most severe manifestation of sepsis, enrolled in the multicenter, randomized clinical trial ALBIOS (Albumin 
Italian Outcome Sepsis study, NCT007071225). Patients were divided into survivors (S) and non-survivors (NS) 
according to 28-day mortality and plasma samples were collected one day (D1) and one week (D7) after diagnosis 
of septic shock. Integration of metabolomics and proteomics information was aimed at revealing molecular path-
ways as well as at identifying molecular features decisive in stratifying the patients.
In our previous study6 we found that profiles of specific metabolites, measured separately at D1 and at D7, 
markedly differed between survivor and non-survivor patients. More precisely, we observed that low unsaturated 
long-chain phosphatidylcholines (PCs) and lysophosphatidylcholines (lysoPCs) species were associated with 
mortality together with circulating kynurenine. Therefore, we speculated that lipid homeostasis and tryptophan 
catabolism might influence mortality in septic shock.
In light of these considerations, the aim of this study is to integrate our previous metabolomics results with 
the information derived from the proteomics analyses in order to have a more complete picture of the changes 
occurring during one week of treatment at the molecular level and to gain deeper insights into septic shock pro-
gression and individual patient’s response. Furthermore, as there are no established approaches or guidelines for 
integrating metabolomics and proteomics data, we adopted different techniques (i.e. regression analysis methods 
that performs both variable selection and regularization and partial least squares discriminant analysis) so to 
compare the features selected and their importance in different models.
Our findings confirmed that non-survivors have different trend in plasma levels of lipid species in comparison 
to survivors, in line with our previous work6. The novelty of this study is the integration with proteomics data, 
which enables to highlight key features associated with the outcome. More precisely, our approach for integrat-
ing metabolites and proteins showed that the proteins decisive in stratifying the patients are those related to the 
inflammatory response and the coagulation cascade, which are known to play an important role in septic shock 
progression, thus reinforcing the feasibility and robustness of our integrative approach.
Results
Clinical characteristics of the study population. Patients with severe septic shock enrolled in the multi-
center ALBIOS clinical trial5, and fulfilling the inclusion/exclusion criteria as previously reported, were analyzed. 
The baseline characteristics of these 17 patients, including site and cause of infection were reported in Table 1. In 
9 patients, the cause of infection was identified at site culture, including gram-negative (4 patients), gram-positive 
(2 patients) and both gram-negative and gram-positive bacterial infection (gram mix, 2 patients), as well as other 
microorganisms (mixed, 1 patient). Two patients (one S and one NS), had multiple site of infection (S abdomen 
and other, NS lungs and other). Patients received antibiotic therapy empirically decided during the first 24 hours. 
Patients were randomized to receive either 20% albumin and crystalloid solutions (10 patients) or crystalloid 
solutions alone (7 patients) for volume replacement. There was not a significant association between mortality 
and the kind of fluid administered. On day 28, mortality rate was 47% (8 patients died). Clinical and laboratory 
variables on day 1 (D1) and day 7 (D7) were reported in Table 2. All the patients were treated according to the 
ALL PATIENTS S NS
Age (years) 66.1 ± 13.9 63. 8 ± 16.6 67.9 ± 12.5
BMI (kg/m2) 27 ± 3.9 27.5 ± 3.9 27.9 ± 3.2
Source of infection
Lungs [no. (%)] 6 (35%) 1 (11%) 5 (63%)
Abdomen [no. (%)] 8 (47%) 4 (44%) 2 (25%)
Genitourinary [no. (%)] 5 (29%) 5 (56%) 0 (0%)
Other [no. (%)] 3 (18%) 1 (11%) 2 (25%)
Type of infection
Negative [no. (%)] 8 (47%) 3 (33%) 5 (63%)
Mixed [no. (%)] 1 (6%) 0 (0%) 1 (13%)
Gram positive [no. (%)] 2 (12%) 1 (11%) 1 (13%)
Gram negative [no. (%)] 4 (24%) 3 (33%) 1 (13%)
Gram mix [no. (%)] 2 (12%) 2 (22%) 0 (0%)
Table 1. Site and cause of the primary infection in survivors (S) and non-survivors (NS). For 8 patients (3 S and 
5 NS) the bacterial culture were negative (Negative). No statistically significant differences were found between 
the two groups.
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standard guidelines internationally accepted for patients with severe sepsis or septic shock at the time of the 
study7.
Changes in protein abundances between groups. A multi-iTRAQ experiment was designed to com-
pare the plasma protein profile between S and NS patients. Criteria for proteins selection are described in details 
in the Supplemental Methods. In total, from an average of 3000 proteins detected, 132 were selected for further 
analyses, i.e. only proteins detected with at least two unique peptides in all the 6 iTRAQ experiments. According 
to Gene Ontology analysis (Slim Biological Process analysis, p < 0.05), these proteins were classified into blood 
coagulation, complement activation, vitamin transport, cell-cell adhesion, proteolysis and nucleobase-containing 
compound metabolic processes. For the significant proteins, extended name and main functions are reported in 
Table S1.
We first assessed by univariate analysis if protein levels were significantly different between S and NS sepa-
rately at the two time points (Wilcoxon rank-sum test p < 0.05, FDR < 0.15). Proteins P02745, Q86VB7, Q96PD5 
and Q9Y5Y7 were significantly different between S and NS at D1 and proteins P05543, P13796 and P36222 at D7 
(Fig. 1, extended names of the proteins are reported in the legend). Proteins values were reported as normalized 
peak intensities. As illustrated in the Supplemental material, the raw peak intensities were log2 transformed and 
LOESS normalized against mean global intensity from all 6 iTRAQ™ 8-plex experiments.
Time trend variation of proteins and metabolites. Changes in proteins abundance from D1 to D7 
within the same group were also assessed; 14 proteins significantly changed from D1 to D7 in the NS group and 
10 in the S group (Mann-Whitney t-test p < 0.05, FDR < 0.15). Among them, 9 were significantly different from 
D1 to D7 in both groups. Temporal trends in the two groups were reported in Table 3. Proteins abundances were 
expressed as normalized peak intensities. Differences in the ratio D7/D1 between S and NS patients for metabo-
lites and proteins are shown in Figs 2 and 3. Five metabolites, belonging to lipid species and biogenic amines class, 
and 8 proteins were significantly different between the two groups.
Multivariate analysis. Regression model from targeted metabolomics data. We used regression models with 
the aim of identifying the set of features which were mostly associated to the target class, i.e. the non-survivors 
(NS). The coefficients of the models obtained from metabolomics concentrations only are reported in Table S5.
D1 D7
S NS S NS
Heart Rate (bpm) 103.5 ± 28.4 106.1 ± 12.8 80.4 ± 11.0 91.1 ± 8.7
Mean Arterial Pressure (mmHg) 76. 6 ± 18.3 72.0 ± 11.0 96.3 ± 13.8* 78.4 ± 12.0*
Central Venous Pressure (mmHg) 11.4 ± 5.8 11.5 ± 4.4 7.9 ± 5.1 8.8 ± 2.1
Urine output (mL/day) 2556.1 ± 918.4 1840.0 ± 1652.8 3705.6 ± 1580.2* 1737.5 ± 1478.9*
FiO2 (%) 59.7 ± 12.4 56.3 ± 20.8 40.6 ± 8.5 46.3 ± 23.4
ScvO2 (%) 73.3 ± 11.6 78.5 ± 7.5 77.1 ± 7.3 77.9 ± 4.5
PvCO2 (mmHg) 46.8 ± 5.7 47.8 ± 4.9 50.6 ± 5.2 46.5 ± 7.8
PaCO2 (mmHg) 42.3 ± 6.3 44.3 ± 6.4 45.3 ± 3.9 41.6 ± 8.3
PvO2 (mmHg) 43.3 ± 4.6 46.5 ± 7.4 44.1 ± 5.9 44.6 ± 5.9
PaO2 (mmHg) 122.2 ± 61.0 98.5 ± 32.0 126.9 ± 29.8 115.1 ± 61.0
PEEP (cmH2O) 8.5 ± 2.5 5.3 ± 5.4 8.9 ± 2.4 8.6 ± 3.4
Lactate (mmol/L) 3.0 ± 1.6 5.0 ± 2.3 1.4 ± 0.5 2.4 ± 2.2
Platelets (×103/mm3) 63.9 ± 35.4 61.4 ± 68.1 112.0 ± 67.2 80.3 ± 50.9
Creatinine (mg/dL) 2.7 ± 0.9 2.1 ± 1.3 1.8 ± 1.7 1.8 ± 1.5
Biluribin (mg/dL) 1.7 ± 0.9 5.0 ± 4.8 1.9 ± 1.3 9.1 ± 10.8
Presepsin (µg/L) 1486 ± 1256 2673 ± 2351 830 ± 458 4969 ± 5826
Renal Repl Therapy (RRT)[no. (%)] 0 (0%) 2 (25%) 1 (11%) 3 (38%)
Ventilatory Support [no. (%)] 9 (100%) 8 (100%) 4 (44%) 7 (88%)
Sofa score
Overall 11.3 ± 2.4 12.4 ± 3.2 5.0 ± 2.1 9.3 ± 5.1
Respiratory System 2.4 ± 1.0 2.4 ± 1.3 1.2 ± 0.8 1.9 ± 1.0
Coagulation 2.3 ± 0.9 2.5 ± 1.4 1.6 ± 1.1 1.9 ± 1.2
Liver 1.1 ± 0.9 1.9 ± 1.2 1.0 ± 1.0 2 ± 1.8
Cardiovascular System 3.6 ± 0.5 3.6 ± 0.5 0.0 ± 0.0 1.1 ± 1.5
Renal System 1.9 ± 0.6 2.0 ± 1.7 1.2 ± 1.5 2.4 ± 1.8
Table 2. Clinical and laboratory variables at D1 and D7 for the 17 patients, divided in survivors (S, 9 pts) and 
non-survivors (NS, 8 pts). Data are presented as mean ± SD or as frequency. Mean Arterial Pressure and Urine 
output (marked with *) at D7 were significantly different between the two groups (p-value < 0.05 Wilcoxon 
rank-sum test).
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Three metabolites were selected in all models: two diacyl-phosphatidylcholine species (PC aa C42:6, PC aa 
C36:6) and tyrosine. Figure 4A shows the coefficient values of the model built according to the criterion of min-
imal deviance on the first 30 ranked features. All the obtained models correctly classified the observations in the 
testing set.
Regression model from targeted metabolomics and proteomics data. We built the regression 
models combining metabolomics and proteomics data, as described in the methods section. The coefficients of 
the models were reported in Table S6. Figure 4B shows the coefficient values of the model built according to the 
Figure 1. Boxplot of protein peak intensities significantly different between S (blue) and NS (orange) at D1 
(A) and D7 (B) (Wilcoxon rank-sum test p < 0.05, FDR <0.15). Distribution of differences is shown as box-
plot. Each plot represents a different protein: P02745, Complement C1-q subcomponent subunit A; Q86VB7, 
Scavenger receptor cysteine-rich type 1 protein M130; Q96PD5, N-acetylmuramoyl-L-alanine amidase; 
Q9Y5Y7, Lymphatic vessel endothelial hyaluronic acid receptor 1; P05543, Thyroxine-binding globulin; P13796, 
Recombinase Flp protein; P36222, Chitinase-3-like protein 1.
S NS
D1 D7 TREND D1 D7 TREND
P00751 16.704 (16.203,17.223) 16.308 (16.183,16.619) ↓ 17.004 (16.665,17.101) 16.630 (16.122,16.759) * ↓
P01011 17.046 (16.880,17.197) 16.799 (16.493,17.059) ↓ 17.292 (16.897,17.452) 16.509 (16.228,16.994) * ↓
P02649 15.413 (14.987,15.639) 15.691 (15.234,16.187) ↑ 15.222 (15.077,15.757) 16.347 (16.001,16.892) * ↑
P02741 17.228 (16.847,18.673) 15.921 (15.482,16.165) * ↓ 18.037 (17.845,18.162) 16.385 (15.815,16.683) * ↓
P02750 17.099 (16.557,17.530) 16.510 (15.985,16.653) * ↓ 17.445 (16.468,17.906) 16.611 (15.951,17.189) * ↓
P06681 15.394 (15.059,15.611) 14.951 (14.627,15.195) * ↓ 15.579 (15.479,15.909) 15.446 (15.129,15.582) * ↓
P07358 15.294 (14.675,15.771) 14.908 (14.361,15.434) ↓ 14.573 (14.521,15.862) 14.434(14.298,15.415) * ↓
P07360 15.731 (15.366,16.235) 15.434 (15.343,15.690) * ↓ 15.889 (15.530,16.313) 15.490 (15.107,15.969) * ↓
P15169 14.701 (14.506,15.917) 14.482 (14.119,15.433) ↓ 14.922 (14.082,15.805) 14.641 (13.806,15.523) * ↓
P18428 15.553 (14.594,15.776) 14.077 (13.318,14.515) * ↓ 15.485 (14.620,15.728) 14.378 (13.827,14.895) * ↓
P22792 14.339 (14.097,14.900) 14.112 (13.789,14.686) * ↓ 14.521 (14.228,14.798) 14.190 (13.916,14.551) * ↓
P25311 16.106 (15.665,16.971) 17.427 (16.729,17.668) * ↑ 16.466 (15.381,17.172) 17.398 (16.155,17.793) * ↑
P36222 13.330 (12.748,14.194) 11.798 (11.524,11.972) * ↓ 14.467 (14.065,14.723) 12.388 (12.076,13.035) * ↓
P49908 13.549 (13.239,14.047) 14.240 (14.188,14.828) * ↑ 13.163 (12.914,13.674) 13.938 (13.582,14.338) * ↑
Q15582 14.452 (13.352,14.611) 13.777 (12.819,14.227) * ↓ 14.157 (13,277, 14,384) 14.079 (13.147, 14.143) ↓
Table 3. Values of protein abundance in survivors (S) and non-survivors (NS) at D1 and at D7. Significant 
differences between D1 and D7 are marked with * (Wilcoxon sign-rank test p < 0.05, FDR < 0.15). Plasma 
concentrations are expressed as peak intensities and shown as median (25, 75 percentiles). Acronyms: P00751, 
Complement factor B; P01011, Alpha-1-antichymotrypsin; P02649, Apolipoprotein E; P02741, C-reactive 
protein; P02750, Leucine-rich alpha-2-glycoprotein; P06681,Complement C2; P07358, Complement 
component C8 beta chain; P07360, Complement component C8 gamma chain; P15169, Carboxypeptidase N 
catalytic chain; P18428, Lipopolysaccharide-binding protein; P22792, Carboxypeptidase N subunit 2; P25311, 
Zinc-alpha-2-glycoprotein; P36222, Chitinase-3-like protein 1; P49908, Selenoprotein P; Q15582, Transforming 
growth factor-beta-induced protein ig-h3.
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criterion of minimal deviance on the first 30 ranked features. From Tables 4 and S6 we can notice that lysophos-
phatidylchiline C24:0 (lysoPC a C24:0) and the complement C1q A chain (protein P02745) were selected by all 
models. Moreover, two diacyl-phospatidylcholine species (PC aa C36:3 and PC aa C42:6) were again selected in 
these models, and their coefficients maintain the same sign as in previous ones. All the obtained models correctly 
classified the observations in the testing set.
Classification model from targeted metabolomics, proteomics and clinical data. Finally, we 
built a model combining metabolomics, proteomics and clinical data as described in the Methods section. The 
coefficients of the models are reported in Table S7 and Fig. 4C shows the coefficient values of the model built 
according to the criterion of minimal deviance on the first 30 ranked features. We could notice that also in these 
models the protein P02745 appeared among the most important predictors, as also confirmed by discriminant 
analysis (Table 4). Another protein, i.e. Hemopexin (P02790), and the metabolite PC aa C34:3 were also selected 
by all models. All the obtained models correctly classified the observations in the testing set.
Discriminant analysis. Table 4 reports the coefficient values of the LDA models and the VIP scores of the 
PLS-DA models built on the first 10 and 20 ranked features as described in the Methods section.
In the metabolites model, PC aa C36:3 occupied the second and first position in the VIP ranking, when con-
sidering 20 and 10 features respectively. As for the integrated model, P02745 was in the first position and lysoPC 
a C24:0 the third (20 feature model) and second (10 feature model), thus confirming the importance of these fea-
tures already emerged from the regression analysis. In the classification models for omics and clinical data and for 
metabolomics and proteomics data, we could notice that P02745 occupied the first position followed by another 
protein, i.e. P02790, in agreement to what emerged from the regression analysis. Three-dimensional PLS-DA 
score plots on 20 features for the three models are shown in Fig. 5. In all cases, the groups separated perfectly.
Figure 2. Boxplot of the ratio D7/D1 of metabolite concentrations (µM) significantly different between S (blue) 
and NS (orange) (Wilcoxon rank-sum test p < 0.05, FDR <0.15).
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Discussion
The analyses here reported represent a proof-of-concept study, which demonstrates the feasibility of integrating 
different levels of biological measurements (metabolomics and proteomics) with clinical variables in a longitudi-
nal study providing incremental discriminative capability for mortality risk assessment.
The novelty and the challenge of our approach was to use a large number of variables in a small but 
well-characterized population and to apply the most suitable data-mining tools to find the best subdivision in the 
variable domain to separate non-survivors from survivors. The aim was to characterize non-survivors patients 
according to the variation of biological features that occurred from acute phase (D1) to steady state (D7). Our 
methodology was based on ranking the species which changed from D1 to D7 in order to find the ones most 
related to the outcome or those that, although not significant alone, could highlight important association to 
particular pathways.
In this work, our previous results6 and literature findings8,9 were confirmed: lipidome alteration was a prom-
inent component of the metabolic phenotype in non-survivors patients with septic shock. A clear bio-signature 
characterizing non-survivors was their reduction over time in circulating PC species, containing long chain pol-
yunsaturated fatty acid, such as PC aa C42:6, PC aa C40:6, and lysoPC species (Fig. 4A). As already mentioned 
in our previous work6, such lowered PC and lysoPC species could hamper their protective effects10,11 and con-
ceivably their reduction, especially lysoPC species, may also promote an excessive immune response12. We also 
observed an imbalance in plasmalogens (PC ae) levels over time between NS and S. Plasmalogens serve as endog-
enous antioxidants, mediators of membrane structure and dynamics, storage for polyunsaturated fatty acids and 
lipid mediators13. Raising PC ae levels protects human endothelial cells during hypoxia14 while their reduction 
might reflect an increased oxidative imbalance probably due to an excessive systemic inflammatory response15.
An exaggerated systemic inflammatory response in non-survivors would be in accordance with the observed 
overall increase level of methylarginines (total dimethylarigine, DMA; symmetric dimegthylargine, SDMA; 
Fig. 2) reported to impair macrophage functions16 and to be associated with increased mortality in patients with 
severe sepsis17.
Such considerations are in line with proteomics findings. Significant changes in abundance between NS and 
S mainly involved those proteins which belong to the coagulation, innate immunity and inflammatory response 
pathways, whose importance has already been recognized in sepsis and septic shock settings18. Many works in 
Figure 3. Boxplot of the ratio D7/D1 of protein normalized peak intensities, which are significantly different 
between S (blue) and NS (orange) (Wilcoxon rank-sum test p < 0.05, FDR <0.15). Each plot represents a 
different protein: P00746, Complement factor D; P00915, Carbonic anhydrase 1; P02649, Apolipoprotein E; 
P02745, Complement C1q subcomponent subunit A; P02746, Complement C1q subcomponent subunit B; 
P02765, Alpha-2-HS-glycoprotein; P05155, Plasma protease C1 inhibitor; P18065, Insulin-like growth factor-
binding protein 2; Q9Y5Y7, Lymphatic vessel endothelial hyaluronic acid receptor 1.
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literature have described modulation in plasma proteins in the complement, coagulation, and fibrinolytic cas-
cades in sepsis survivors and non-survivors19,20.
The interplay between these pathways were further highlighted by our integration analyses where lower over 
time variation of Complement C1-q proteins (P02745, P02746) and Hemopexin (P02790) were the most relevant 
features for non-survivors. The classical pathway of complement activation represents a link between innate and 
adaptive immunity. It is activated when Complement C1-q binds a target cell (apoptotic cell or bacteria) express-
ing membrane PC or antigen/antibody complexes. The activated complement cascade produces inflammatory 
mediators that stimulate leukocytes and lymphocytes migration. This set of events lead to the lysis of the target 
cell21,22. It is likely that lower variation of C1 complex proteins over one week may indicate worse pathogen clear-
ance and inflammation control in non-survivors compared to survivors. The integration of omics data with clin-
ical variables reinforced the results that low variation in complement C1 and PC metabolic species are associated 
with poor outcome.
Similarly, lowered Hemopexin (P02790) could imply difficulties in non-survivors to counteract inflammation. 
Hemopexin is an heme-binding plasma glycoprotein with anti-inflammatory action probably trough the inhibi-
tion of inflammatory cytokine production23,24. Its decrease over time in non-survivors is in accordance with the 
low hemopexin serum levels related with poor prognosis of septic shock patients25.
Non-survivors were also characterized by an increase in the abundance over-time of Cystatin-C (P01034), 
whose accumulation in plasma has been related to renal dysfunction26. A worsening of renal function estimated 
by enhanced Cystatin-C rather than by creatinine has been recently described in septic patients with acute kidney 
injury (AKI) presenting higher Cystatin C levels than non-AKI septic patients27. Despite we did not observe sig-
nificant differences in SOFA score for renal function between the two groups, this value increased from D1 to D7 
in non-survivors whereas it decreased in survivors (Table 2)
Integrated models with clinical data are of difficult interpretation, probably due to the fact that we considered 
a long time interval (7 days). In spite of this, the negative association of MAP (Mean Arterial Pressure) with the 
outcome was expected since the duration of hypotension or a limited recovery of MAP values is an important pre-
dictor of mortality28,29. Increase of CVP (central venous pressure) and PEEP (Positive End-expiratory pressure) 
over time were also indicative of poor outcome in our integrated model. In fact, in the interaction between arterial 
circulation, organ perfusion and venous circulation, CVP represents the downstream pressure and the increase in 
downstream pressure may generate congestion30.
Age was not considered in our model as our cohort has a limited range in age. Indeed, no significant age 
differences were found between survivor and non survivors. The range of age in people affected by sepsis is very 
Figure 4. Coefficient values of the logistic regression models built according to the criterion of minimal 
deviance on the first 30 ranked features. Each panel represents a regression model built on metabolomics 
data only (panel A), metabolomics and proteomics data (panel B) and on omics data and clinical parameters 
(panel C). Acronyms: P01034, Cystatin-C; P19823, Inter-alpha-trypsin inhibitor heavy chain H2; P06276, 
Cholinesterase; O75822, Attractin; P02746, Complement C1q subcomponent subunit B; P02745, Complement 
C1q subcomponent subunit A; P02790, Hemopexin; P20851, C4b-binding protein beta chain; CVP: Central 
Venous Pressure; PEEP: Positive End-expiratory pressure; PAC: PaCO2; MAP: Mean Arterial Pressure.
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PROTEINS
VIP PLS-
DA 20
PLS-DA 
10 LDA
METABOLITES 
PROTEINS CLINICAL 
DATA
VIP PLS-
DA 20
VIP PLS-
DA 10 LDA
PC aa C42:1 1.633 — — P02745 1.438 1.576 −4.822 P02745 1.681 1.620 −15.017
PC aa C36:3 1.400 1.516 10.290 PC aa C36:3 1.367 — — P02790 1.455 1.412 1.349
lysoPC a C24:0 1.372 1.411 0.200 lysoPC a C24:0 1.324 1.433 −2.041 PC ae C44 4 1.334 — —
lysoPC a C17:0 1.233 — — P19823 1.282 — — PvCo2 1.308 — —
PC aa C42:6 1.159 1.120 1.785 PC aa C42:6 1.267 — — PEEP 1.235 1.053 5.906
PC ae C30:1 1.137 — — P02746 1.249 — — PaCO2 1.229 — —
PC aa C34:3 1.118 — — P02790 1.223 — — PC aa C34 3 1.124 1.030 0.172
Tyr 1.096 1.042 7.865 P05543 1.053 1.092 1.627 FiO2 1.061 — —
Pro 1.058 — — PC aa C34:3 1.035 — — Creatinine 0.986 — —
Creatinine 0.965 — — PC aa C42:2 0.936 1.006 0.729 Urine Output 0.984 0.794 8.590
PC ae C42:1 0.915 0.827 −3.442 PC ae C42:1 0.909 — — P05543 0.896 — —
PC ae C30:2 0.858 0.836 6.010 SM OH C16:1 0.876 0.782 −0.979 MAP 0.847 0.825 −1.140
PC aa C42:2 0.815 0.886 −6.153 O75882 0.866 0.920 0.961 Bilirubine 0.814 0.601 6.668
SM C24:1 0.756 — — P22792 0.801 0.826 −2.583 P06276 0.659 — —
PC aa C42:5 0.753 — — P16070 0.745 0.653 1.940 Lactate 0.601 0.268 −1.285
SM OH C16:1 0.639 0.747 −13.680 P20851 0.721 0.438 −0.326 CVP 0.559 — —
PC ae C34:3 0.600 0.417 — P06276 0.629 0.706 0.692 Heart Rate 0.552 0.789 6.036
PC aa C36:6 0.585 — −3.395 Q14520 0.533 — — ScvO2 0.522 — —
PC aa C34:4 0.521 0.686 1.921 PC ae C34:3 0.397 — — P16070 0.515 0.919 6.023
PC ae C44:4 0.266 — — PC ae C44:4 0.232 — — pHa 0.266 — —
Table 4. Values of VIP scores of the PLS-DA models built on the first 10 and 20 ranked features and the 
coefficient values of LDA models. The tables summarize the results of the models on metabolites only, 
metabolites and proteins and the integration of metabolomics, proteomics and clinical data, respectively.
Figure 5. Three-dimensional PLS-DA score plots on the first ranked 20 features for three different models. 
Each panel represents a model built on metabolomics data only (panel A), metabolomics and proteomics data 
(panel B) and on omics data and clinical parameters (panel C).
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wide31. Consequently, age could be a factor if the cohort under study is very heterogeneous in terms of age and 
this was not our case.
Importantly, no significant associations between type of fluid administered and mortality was observed in our 
study population, which is a subset of a larger cohort in the well-defined clinical trial ALBIOS. Indeed, the study 
on ALBIOS database5 showed that in patients with severe sepsis, albumin replacement in addition to crystalloids, 
as compared with crystalloids alone, did not improve the rate of survival at 28 and 90 days. Thus our results are in 
line with what observed for the entire database.
We are aware of the limitations of our study. First of all, the size of the datasets used to build the classification 
models is small. However, we tried to reduce the confounding factors by focusing on a homogeneous group of 
patients, i.e. severe septic shock ones. We thus hypothesized that the changes observed are mainly related to shock 
progression and different prognoses. Moreover, we measured metabolites and proteins at two time points only 
within one week from the diagnosis of septic shock, and biological features with temporal changes out of this time 
window might provide a more precise insight for the clinical progression of the disease.
Finally, we are aware that selected features before the multivariate analyses certainly affect the successive anal-
yses, but we think that our methodological pipeline may represent an acceptable trade-off approach. The filter 
approach was necessary to avoid unreliable results, as the features are highly correlated and the logistic regression 
applied to such type of dataset may not be consistent. Feature reduction is extremely useful when a model is 
affected by multicollinearity, as in our case32,33. In fact, if we have high collinearity and a condition where number 
of feature p is much higher than the number n of observations, the algorithm for the coefficients estimate can fail, 
the overall significance of the model is compromised and the estimate of the regression coefficient can be inac-
curate. Therefore, our decisions were driven by the characteristics of our data (i.e. strongly correlated features) 
and by the size of our dataset: low number of observations (patients) with respect to high number of variables 
(metabolites, proteins, clinical features)
We must also recall that we are not interested in prediction but in the development of an approach to describe 
the current dataset and to identify the main pathways involved in pathology progression within the studied 
cohort.
Conclusions
In conclusion, for the first time in patients with sepsis, our integrative approach was able to capture possible 
evolution and variations of metabolic and proteomic signatures during a well-established pathophysiologic man-
ifestation of severe septic shock.
Changes in the abundance of metabolites and proteins within seven days from diagnosis could distinguish 
survivors and non-survivors among severe septic shock patients. Our data reinforced the emerging evidence 
that lipidome alterations might influence mortality in septic shock, probably by a cross-talk with inflammatory 
responses. This study also showed that the combination of proteomics and metabolomics data provides a more 
complete view of mortality orchestrators, interconnecting complement system and inflammation. Although fur-
ther validations are needed in a bigger cohort, our results may constitute an important step toward the investiga-
tion of combined therapeutic strategies targeted at alteration of both inflammation susceptibility and coagulation 
cascade.
Material and Methods
Study design, patients and clinical data. This pilot retrospective investigation was an ancillary study of 
the multicenter, randomized Albumin Italian Outcome Sepsis (ALBIOS) clinical trial. It enrolled patients with 
severe sepsis or septic shock from 100 ICUs in Italy (NCT00707122), as fully described in the original article34.
The study was compliant with the 1975 Declaration of Helsinki as revised in 2008, and approved first by the 
Institutional Review Board of the Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan, Italy 
(coordinating center), and subsequently by the appropriate institutional review boards of all the other participat-
ing centers. Written informed consent or deferred consent was obtained from each patient. Patients were man-
aged by the clinical care team according to international guidelines. Patients were randomly assigned to receive 
either 20% albumin and crystalloid solution or crystalloid solution alone. During the early phase of volume 
resuscitation, fluids were administered in both groups according to early goal-directed therapy.
Inclusion criteria for the present study are the same as in6. We briefly recall them herein: presence of septic 
shock, serum concentrations of lactate >4 mmol/L, a total SOFA score >8, and availability of plasma samples at 
day 1 and day 7 in the ALBIOS biobank. In addition, we consider only patients remaining in ICU until 7 up to 
14 days from shock onset (until either ICU discharge or death). Exclusion criteria were: presence of active hema-
tological malignancy or cancer, immunodepression, HIV infection, chronic renal failure, or advanced cirrhosis. 
Such inclusion and exclusion criteria were in accordance with those of the multicenter clinical study, ShockOmics 
(NCT02141607), and the current study represents a proof of concept study in view of further patient cohort. Only 
20 among the 997 patients enrolled in ALBIOS trial and with plasma samples stored in the biobank fulfilled the 
inclusion criteria. Three out of 20 available patients have been excluded from the present study due to technical 
problems in handling the plasma samples for proteomics analysis.
The following demographic, clinical and laboratory variables were considered: (i) demographic and anam-
nestic information collected at ICU admission, at day 1 and at day 7: age (years), sex, body mass index, source 
of infection and type of infection; (ii) hemodynamic parameters: heart rate (bpm), mean arterial pressure 
(mmHg), central venous pressure (mmHg), daily urinary output (ml/die); (iii) ventilation parameters: posi-
tive end-expiratory pressure (cmH20), inspiratory oxygen fraction –FiO2 (%); (iv) blood gas analysis: central 
venous O2 saturation, venous partial pressure of CO2, arterial partial pressure of CO2, arterial partial pressure of 
O2, central venous partial pressure of O2, arterial and venous pH; (v) laboratory and clinical parameters: serum 
concentrations of creatinine (mg/dL), bilirubin (mg/dL), lactate (mmol/L), platelet count (x103 cells/mm3); (vi) 
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Sequential Organ Failure Assessment Score (SOFA) in order to assess daily organ functions35, total SOFA score 
and the sub-scores relating to the respiratory, coagulation, hepatic, cardiovascular, and renal systems; (vii) use of 
renal replacement therapy (continuous venous-venous hemofiltration), need for ventilatory support. We consid-
ered the mortality at day 28 as primary outcome.
For each patient, plasma samples were collected on day 1 (acute phase, D1) and on day 7 (steady state; D7) 
after study enrolment.
Proteomics. A multi-iTRAQ (isobaric Tags for Relative and Absolute Quantitation) experiment for simul-
taneous determination of both the identity and relative abundance of proteins was designed to compare plasma 
protein pattern expression between S and NS patients. Details about sample preparation, LC-MS/MS analyses, 
protein identification and data files availability are reported in Supplemental Information. In particular, the 
following criteria were used for proteins selection: 1) only proteins identified in all iTRAQ experiments were 
included; 2) contaminant proteins (i.e. the most abundant proteins that should be previously depleted in the 
immunodepletion process) were removed; 3) only proteins quantified with at least two unique peptides were 
included. After this selection, 132 proteins were considered for further analyses.
Targeted metabolomics. A targeted quantitative approach using a combined direct flow-injection and 
liquid chromatography (LC) tandem mass spectrometry (MS/MS) assay (AbsoluteIDQ 180 kit, Biocrates, 
Innsbruck, Austria) was applied for the metabolomics analysis of plasma. Methodological details and data pre-
processing have been extensively reported in our previous articles6,36 and in the Supplemental Information. 
Briefly, the method combines derivatization and extraction of analytes with the selective mass-spectrometric 
detection using multiple reaction monitoring (MRM) pairs. Isotope-labeled internal standards are integrated 
into the platform for metabolite absolute quantification. This strategy allows simultaneous quantification of 186 
metabolites (40 amino acids and biogenic amines, 40 acylcarnitines, 90 glycerophospholipids, 15 sphingomyelins, 
1 monosaccharide). A metabolite was excluded from further analysis if its concentration did not meet all the fol-
lowing criteria: (1) fewer than 20% of missing values (non-detectable peak) for each quantified metabolite in each 
experimental group (2) 50% of all sample concentrations for the metabolite had to be above the limit of detection 
(LOD). In total, 137 of the 186 metabolites expressed as pg/ml were considered for statistical analysis. The list of 
all the measurable metabolites and the plasma concentration of the metabolites for each patient are provided in 
Supplemental Information (Tables S2–S4).
Multivariate analysis. Data from targeted metabolomics analyses. The aim of our model was to classify NS 
patients, in particular to find the species which are mostly associated with the outcome. We built the model on the 
ratio D7/D1 of metabolite concentrations. Because of the small sample size (17 patients) and the large number 
of features (137 metabolites), collinearity represents a crucial issue. The method used to reduce the number of 
features is the minimal-redundancy-maximal-relevance (mRMR)37, a filter algorithm based on the mutual infor-
mation (freely available at http://home.penglab.com/proj/mRMR/). This algorithm ranks features according to 
their correlation to the outcome (maximum relevance of the feature) and to which information is not explained 
by the features already selected (minimum redundancy). We considered the first 10, 20 and 30 ranked metabolites 
to build three different classification models. Data were first normalized (Z score normalization) and the dataset 
was divided into a training and test set as two third and one third of the observations, respectively.
We adopted two strategies to further select a smaller subset of features. We performed 50 times an elastic net 
logistic model using a logit function to fit the training set data (lasso and lassoglm routines in Matlab® enviro-
ment). We decided to use elastic net, as it was proposed to overcome the limits of lasso in cases like our38. Indeed, 
when the number of observation n is much higher than the number of features p, the lasso selects at most n var-
iables before it saturates, because of the nature of the convex optimization problem. This seems to be a limiting 
feature for a variable selection method. If there is a group of variables among which the pairwise correlations are 
very high, then the lasso tends to select only one variable from the group and does not care which one is selected. 
We decide to use 𝛼 = 0.5, i.e. the weight of lasso (L1) versus ridge (L2) optimization, as a good compromise.
We considered a binary classification (S = 0, NS = 1) and the output of the model is a value between 0 and 1, 
which represents a sort of probability. We then selected the coefficients of the model with the minimal deviance. 
We also applied another strategy, instead of the coefficients we select the shrinkage parameter λ, corresponding 
to the model with the minimal deviance, and we used it to fit the elastic net model on the training set to obtain 
the coefficients of the logistic regression. In both cases, the models were then evaluated on the testing set and the 
performance were assessed by the number of correct imputations.
Linear Discriminant Analysis (LDA) and Partial Least Squares Discriminant Analysis (PLS-DA) were also 
used (toolbox freely available at http://www.libpls.net). More precisely, LDA was performed on the first 10 ranked 
metabolites and the coefficients for the linear boundary between the first and second classes were retrieved. 
PLS-DA was performed both on the first 10 and 20 ranked metabolites, considering 3 PLS components. Since 
the groups are unbalanced, the data matrix was weighted centered in order to avoid having a decision boundary 
shifted towards the most numerous group. The variable importance in projection (VIP) scores, which represent 
the weights of each feature in PLS-DA model, and the coefficients of LDA were compared to those of logistic 
regression. Also in this case, the performance of the classification models was evaluated by considering the num-
ber of correct imputations.
Integration of targeted metabolomics and proteomics data. We built an integrated model by merging targeted 
metabolomics and proteomics data. Also for proteomics data we computed the ratio D7/D1 for each of the 132 
protein peak intensities. To avoid multicollinearity, the mRMR algorithm was applied and the first 50 ranked 
proteins were selected. These proteins were then combined with the first 50 ranked metabolites and the mRMR 
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was performed again on these new features subset composed of 50 metabolites and 50 proteins. After Z score nor-
malization, we considered the first 10, 20 and 30 ranked features to build the classification models using the two 
strategies described in the previous paragraph. LDA and PLS-DA were also performed as previously described.
Integration of metabolomics, proteomics and clinical data. Finally, we built a comprehensive model which com-
bines targeted metabolomics, proteomics and clinical data. Only continuous clinical variables were considered 
and their ratio D7/D1 was computed. Total SOFA score and partial SOFA scores were not included to avoid any 
redundancy. In fact, they are calculated from clinical parameters which are already included in the model and 
they are thus likely to be correlated. Finally, a total of 17 clinical variables were included. The 17 clinical varia-
bles were added to the first 20 ranked features from the set of metabolites and proteins, obtained as previously 
described. The mRMR was then performed on this subset of features to further reduce the number of features. 
After Z score normalization, the first 10, 20 and 30 ranked features were selected to build the classification mod-
els. LDA and PLS-DA were also performed on this subset of features composed of metabolites, proteins and 
clinical parameters.
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